Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC
Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC
Active, not recruiting · NCT03527108 · Registry updated 2026-05-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2026-05-22 | NCT03527108 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Bristol-Myers Squibb | 422 |
| Eli Lilly and Company | 370 |
| Fox Chase Cancer Center | 58 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fox Chase Cancer Center | Philadelphia | United States | 259 |
| NYU Langone | New York | United States | 34 |